הבדלים בין גרסאות בדף "טנופוביר - Tenofovir"
מתוך ויקירפואה
שורה 17: | שורה 17: | ||
:ב. אף אחת מן התרופות ADEFOVIR, ENTECAVIR, TELBIVUDINE, TENOFOVIR לא תינתן בשילוב עם התרופה האחרת . | :ב. אף אחת מן התרופות ADEFOVIR, ENTECAVIR, TELBIVUDINE, TENOFOVIR לא תינתן בשילוב עם התרופה האחרת . | ||
<hr> | <hr> | ||
+ | '''עדכון סל התרופות 2013'''{{ש}}טיפול בנשאי HIV <hr> | ||
|התוויות= Viread is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1infected adults over 18 years of age. The demonstration of benefit of Viread is based on results of one study in treatment-naive patients, including patients with a high viral load ( > 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure ( < 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml). In deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate | |התוויות= Viread is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1infected adults over 18 years of age. The demonstration of benefit of Viread is based on results of one study in treatment-naive patients, including patients with a high viral load ( > 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure ( < 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml). In deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate | ||
|קיים גם בתכשירים= ATRIPLA ; TRUVADA | |קיים גם בתכשירים= ATRIPLA ; TRUVADA |
גרסה מ־12:09, 5 בינואר 2013
טנופוביר - Tenofovir | ||
---|---|---|
שמות מסחריים | ®VIREAD | |
קבוצה פרמקולוגית (ATC) | "NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS" | |
שם גנרי | "טנופוביר" (קישור לדף התרופה במאגר משרד הבריאות) |
|
סל הבריאות | כלול | |
מסגרת הכללה בסל | עדכון סל התרופות 2012 תרופה מוגבלת לרישום ע"י רופא מומחה או הגבלה אחרת.
2. לטיפול בהפטיטיס B כרונית (התוויה חדשה).
עדכון סל התרופות 2013 טיפול בנשאי HIV |
|
התוויות |
Viread is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1infected adults over 18 years of age. The demonstration of benefit of Viread is based on results of one study in treatment-naive patients, including patients with a high viral load ( > 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure ( < 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml). In deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate
| |
קיים גם בתכשירים | ATRIPLA ; TRUVADA | |